Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin

  title={Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin},
  author={Ken-ichi Nezasa and Kazutaka Higaki and Masaharu Takeuchi and Masayuki Nakano and Masahiro Koike},
  pages={379 - 388}
1. The liver is the target organ for the lipid-regulating effect of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and liver-selective uptake of this drug is therefore a desirable property. The uptake kinetics of rosuvastatin were investigated and compared with those of pravastatin using isolated rat hepatocytes. 2. Uptake for both drugs involved both active transport and passive diffusion processes. The Michaelis constant (K m) of uptake rate for rosuvastatin (9… 

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

Assessment of the role of active uptake relative to the passive process indicated that, at low concentrations, the active process contributes >80% to the overall uptake for 13 drugs, and high passive permeability dominates over transporter-mediated uptake for saquinavir over the full concentration range.

Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.

  • M. SzabóZ. Veres K. Jemnitz
  • Biology, Medicine
    Toxicology in vitro : an international journal published in association with BIBRA
  • 2014

Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure

Absence of Oatp1a/1b uptake transporters increases the systemic exposure of rosuvastatin by reducing its hepatic extraction ratio, but liver concentrations are not significantly affected.

Detection of statin cytotoxicity is increased in cells expressing the OATP1B1 transporter.

The data suggested that uptake transporters have a significant impact on the outcomes of a cell-based assay and should be considered during the early stages of compound toxicity screening in drug discovery.

Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model

Modeling of uptake kinetics in conjunction with metabolism improved the precision of the uptake parameter estimates for repaglinide and telmisartan and reduced the error in certain parameter estimates observed with shorter incubation times.

Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

Interaction of ATV with hepatic uptake transporter organic anion transporting polypeptide (Oatp) and efflux transporter multidrug resistance associated protein 2 (MRP2/Mrp2) in vitro and ex situ and inhibition of Oatp-mediated uptake seems to be the major determinant for interaction between ATV and RIF.

Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model

Rosuvastatin disposition in the IPRL is mediated in part by Oatp1a1 and efflux is almost entirely by Mrp2 and Bcrp, who appear to represent the primary efflux mechanisms for rosuvastatin in the rat.

Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats

Increased expression of CYP3A isoforms and of P-gp occurs with 3 days of exposure to RIT in rats, and might contribute to drug interactions involving RIT (and other antiretroviral agents) in humans.

Statins and myotoxicity: a therapeutic limitation

The present understanding of pathophysiological mechanisms, does not offer a reliable approach to address the same at preclinical level, yet the low incidence of myotoxicty including rhabdomyolysis and less severity of commonly occurring myopathy and myalgia do not raise doubts about the clinical efficacy and tolerability of statins.



Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.

The results of this study indicated that rosuvastatin was taken up by hepatic cells more selectively and more efficiently than pravastatin and simVastatin.

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture.

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

It is demonstrated that the hepatic uptake of pravastatin occurs via a carrier-mediated active transport mechanism utilizing the so-called multispecific anion transporter, which is common with the Na(+)-independent bile acid uptake system, and that this is one of the mechanisms for its selective inhibition of hepatic cholesterol synthesis in vivo.

Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2

Whether a newly cloned organic anion transporting polypeptide (oatp2) transports pravastatin is examined, and the cloned oatp2 was identified as the transporter responsible for the active hepatocellular pravastsatin uptake.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat

Results clarified that rosuvastatin selectively distributed in the liver - the target organ - and was excreted in the bile mainly as the unchanged compound.

Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency.

Transport and binding of methotrexate in vivo.

This mathematical model is used to interpret data on the uptake of methotrexate in bone marrow, spleen, and small intestine of the bile-cannulated rat following intravenous doses of 0.05,0.25, 2.5, and 25 mg./kg.

Preparation of rat liver cells. II. Effects of ions and chelators on tissue dispersion.

  • P. Seglen
  • Biology
    Experimental cell research
  • 1973